Best Practices for Highly Potent API (HPAPI) Development and Manufacturing
Wednesday, July 18th, 11 am - 12pm
Drug product development for highly potent APIs (HPAPIs) can be challenging. Complications with the interface between operations in drug substance and drug product handling can result in increased program complexity and cost.
In this webcast, an API manufacturing expert will present and discuss best practices for developing and manufacturing highly potent compounds; infrastructure requirements that can facilitate development; and accelerated timelines to clinic and market.
Case studies will review the development, rapid scaling, and commercial production of HPAPI drug substance, as well as integrated containment requirements for particle engineering and drug product.
An API manufacturing expert will present and discuss
Philipp Künti, Head of Chemical Manufacturing Small Scale, Lonza Pharma & Biotech
Maurits Janssen, PhD, Senior Director, Head of Commercial Development, Lonza Pharma & Biotech